Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nunzia Pharmaceutical Company (NUNZ)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Medical - Pharmaceuticals
Address
1627 West 14th Street 90813
Long Beach, CA, US
Long Beach, CA, US
CEO
Sara Gonzales
Website
nunziapharma.com
IPO
2009-07-24
CIK 886093 ISIN US67097W1027
Description
Nunzia Pharmaceutical Company operates as a pharmaceutical and nutraceutical company. The company owns the right to manufacture, market, and distribute Nunzia, a nutraceutical that treats autism, fragile X, ADHD, PTSD, and other disorders. It offers its products through wholesalers, as well as through its website nunziapharma.com. The company was formerly known as Arizona Gold and Onyx Mining Company and changed its name to Nunzia Pharmaceutical Company in February 2018. Nunzia Pharmaceutical Company was incorporated in 1986 and is based in Long Beach, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5.9K
Beta
-3.45
Float Shares
78.36M
Free Float %
18.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -96.67% | -99.80% | -99.99% | -99.99% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Levered)
0.00
-99.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-16,905.15
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%—
-
EPS growth Medical - Pharmaceuticals: +20.2%+25.7% ★ Q3'22: -500.0% (vs Q3'21)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%—
-
EBIT margin Medical - Pharmaceuticals: +6.8%—
-
ROIC Medical - Pharmaceuticals: +6.1%-2,487,600.6% Q3'22: +2,098.6% (vs Q3'21)
-
Share dilution Medical - Pharmaceuticals: +0.0%+7.2% Q3'22: +48.4% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×0.00× Q3'22: -0.23× (vs Q3'21)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
1
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BEIJING FEI YUN PROPERTY DEVELOPMENT CO., LTD. | — | 0.00% | — | — | — | — | CO | BEIJING, CHINA | 2003-02-03 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
125.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+125,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2006-10-30 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.02 | 500.00 | 17,513,667 | — | ↗ |
| 2006-10-18 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 100,000 | 0.02 | 1.9K | 17,488,667 | — | ↗ |
| 2006-06-14 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 0.02 | 180.00 | 17,388,667 | — | ↗ |
| 2006-05-03 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 3,913 | 0.04 | 156.52 | 17,378,667 | — | ↗ |
| 2006-05-02 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 55,000 | 0.42 | 23.3K | 17,374,754 | — | ↗ |
| 2006-04-28 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 110,000 | 0.04 | 4.7K | 17,319,754 | — | ↗ |
| 2006-04-14 | Hitz Kingman L | Officer | A-Award | A | Class A Common Shares | 500,000 | 0.02 | 10.0K | 915,202 | — | ↗ |
| 2006-01-30 | HENRY G DAVID | Director / 10% Owner | S-Sale | D | Common Stock | 5,386,667 | 0.00 | — | 17,209,754 | — | ↗ |
| 2005-12-29 | Kron Roger Alan | Director / Officer | A-Award | A | Common Stock | 500,000 | 0.02 | 10.0K | 904,702 | — | ↗ |
| 2005-12-29 | HENRY G DAVID | Director / 10% Owner | P-Purchase | A | Common Stock | 34,698 | 0.04 | 1.3K | 22,596,421 | — | ↗ |
| 2005-12-16 | HENRY G DAVID | Director / 10% Owner | A-Award | A | Common Stock | 2,500,000 | 0.02 | 50.0K | 25,096,421 | — | ↗ |
| 2005-08-08 | Kron Roger Alan | Director / Officer | P-Purchase | A | Common Stock | 245,466 | 0.06 | 15.0K | 404,702 | — | ↗ |
| 2005-08-08 | Hitz Kingman L | Officer | P-Purchase | A | Common Stock | 245,466 | 0.06 | 15.0K | 415,202 | — | ↗ |
| 2005-05-03 | Kron Roger Alan | Director / Officer | P-Purchase | A | Class A Common Stock | 53,333 | 0.09 | 5.0K | 159,236 | — | ↗ |
| 2005-05-03 | Hitz Kingman L | Officer | P-Purchase | A | Class A Common Stock | 53,333 | 0.09 | 5.0K | 169,736 | — | ↗ |
| 2005-04-08 | Kron Roger Alan | Director / Officer | P-Purchase | A | Class A Common Stock | 48,348 | 0.10 | 5.0K | 105,903 | — | ↗ |
| 2005-04-07 | Hitz Kingman L | Officer | P-Purchase | A | Class A Common Stock | 48,348 | 0.10 | 5.0K | 116,403 | — | ↗ |
| 2005-04-01 | FOSSEN WILLIAM J | — | S-Sale | D | Class B Common Stock | 100,000 | 6.50 | 650.0K | 0 | — | ↗ |
| 2005-03-23 | Kron Roger Alan | Director / Officer | P-Purchase | A | Class A Common Stock | 55,555 | 0.09 | 5.0K | 57,555 | — | ↗ |
| 2005-03-23 | Hitz Kingman L | Officer | P-Purchase | A | Class A Common Stock | 55,555 | 0.09 | 5.0K | 68,055 | — | ↗ |
| 2005-03-23 | HENRY G DAVID | Director / 10% Owner | G-Gift | D | Class A Common Stock | 1,000,000 | 1,058,000.00 | 1.06T | 23,561,723 | — | ↗ |
| 2005-03-21 | SANDIFER ROBIN M | Director | P-Purchase | A | CLASS A COMMON STOCK (1) | 1,402,162 | 0.08 | 112.2K | 3,869,363 | — | ↗ |
| 2005-03-17 | Hitz Kingman L | Officer | — | D | Common Shares | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2005-03-17 | FOSSEN WILLIAM J | 10% Owner | J-Other | D | Class A Common Stock Option | 18,300,000 | 0.00 | — | 2,500,000 | — | ↗ |
| 2005-03-17 | FOSSEN MATTHEW W | — | J-Other | D | Class A Common Stock Option | 5,000,000 | 0.06 | 300.0K | 0 | — | ↗ |
| 2005-01-30 | Mills Robert Steve | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-01-30 | Kron Roger Alan | Officer | — | D | Common Shares | 0 | 0.00 | — | 2,000 | — | ↗ |
| 2004-08-26 | HENRY G DAVID | 10% Owner | P-Purchase | A | Class A Common Stock Option (Right to Buy) | 7,500,000 | 0.04 | 300.0K | 7,500,000 | — | ↗ |
| 2004-07-06 | SANDIFER ROBIN M | Director | J-Other | A | Convertible promissory note | 1,761,152 | 0.06 | 105.7K | 1,761,152 | — | ↗ |
| 2004-06-24 | SANDIFER ROBIN M | Director | J-Other | A | Class A Common Restricted Stock Option | 1,000,000 | 0.06 | 60.0K | 1,000,000 | — | ↗ |
| 2004-06-24 | POHLMEIER MARY M | Director | J-Other | A | Class A Common Restricted Stock Option | 1,250,000 | 0.06 | 75.0K | 1,250,000 | — | ↗ |
| 2004-06-24 | FOSSEN WILLIAM J | — | J-Other | D | Class A Common Stock Option | 12,000,000 | 0.06 | 720.0K | 0 | — | ↗ |
| 2004-06-24 | FOSSEN MATTHEW W | Director / Officer | J-Other | A | Class A Common Restricted Stock Option | 5,000,000 | 0.06 | 300.0K | 5,000,000 | — | ↗ |
| 2004-02-04 | HENRY G DAVID | 10% Owner | P-Purchase | A | Class A Common Stock | 625,000 | 0.04 | 25.0K | 5,256,167 | — | ↗ |
| 2003-10-21 | FOSSEN WILLIAM J | Director / Officer / 10% Owner | G-Gift | D | Class A Common Stock | 400,000 | 0.03 | 12.0K | 2,585,750 | — | ↗ |
| 2003-09-29 | HENRY G DAVID | 10% Owner | P-Purchase | A | Class A Common Stock | 400,000 | 0.04 | 16.0K | 4,631,167 | — | ↗ |
| 2003-09-04 | FOSSEN MATTHEW W | Director / Officer | P-Purchase | A | Class A Common Stock | 125,000 | 0.04 | 5.0K | 975,127 | — | ↗ |
| 2003-08-20 | FOSSEN WILLIAM J | Director / Officer / 10% Owner | J-Other | A | Class A Common Stock | 900,000 | 0.00 | — | 2,985,750 | — | ↗ |
| 2003-07-22 | SANDIFER ROBIN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-15 | POHLMEIER MARY M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-11 | SANDIFER ROBIN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-07-01 | SANDIFER ROBIN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-06-25 | SANDIFER ROBIN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-06-18 | SANDIFER ROBIN M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2003-06-18 | HENRY G DAVID | 10% Owner | — | D | Option for Class "A" Common Stock | 5,555,556 | 0.09 | 500.0K | 0 | — | ↗ |
| 2002-01-02 | FOSSEN WILLIAM J | — | J-Other | D | Class A Common Stock Option | 300,000 | 0.20 | 60.0K | 0 | — | ↗ |
| 2000-12-07 | FOSSEN WILLIAM J | — | J-Other | D | Class A Common Stock Option | 1,000,000 | 0.25 | 250.0K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
434.51M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Mitsunaga | President, Chief Financial Officer, Treasurer, Secretary & Director | — | male |
| Sara Gonzales | Chief Executive Officer & Director | — | female |
| Shujie Cui | Chief Medical Officer, Chief Science Officer & Director | — | — |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUNZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
